PTC Therapeutics | PTCT - Zinsaufwendungen Für Schuld

Aktienkurs
68.23
Täglich Wechseln
-0.36 -0.52%
Monatlich
2.22%
Jährlich
37.75%
Q2 Prognose
66.77




Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Cytokinetics USD 30.33M 4.01M 2025-12
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Esperion Therapeutics USD 22.64M 585K 2025-12
Gilead Sciences USD 255M 1000K 2025-12
Incyte USD 582K 10K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
TG Therapeutics USD 6.53M 187K 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 311K 2025-12